Targeted drug combination extends survival in advanced kidney cancer
Results of a phase 1/2 trial led by Roswell Park Comprehensive Cancer Center show that combining the targeted therapies bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progression-free and overall survival in patients with the most common type of kidney cancer.
Read original article on The Medical News →Related news
-
Human challenge study reveals how preexisting immunity affects dengue
United Kingdom
-
Dual-targeting antibody successfully tackles multiple tumor types in mice
United Kingdom
-
Lab-on-a-chip predicts which cancer treatments may work for pediatric acute lymphoblastic leukemia
United Kingdom
-
Rutgers study highlights alarming rise in youth gambling rates
United Kingdom
-
University of Utah researchers discover backup energy system in the heart
United Kingdom
-
Your bottom shape doesn't reveal your estrogen levels—despite what social media says
United Kingdom
-
Combining targeted therapies significantly boosted survival in kidney cancer study
United Kingdom
-
Nature-Inspired Tech Prevents Microplastics Entering Atlantic Ocean Through Wastewater
United Kingdom